Estrogen-induced loss of estrogen receptor (ER) ␣ expression limits estrogen responsiveness in many target cells. However, whether such a mechanism contributes to changes in vascular endothelial ER␣ and/or ER␤ levels is unclear. Using RT-PCR assays, we did not find any regulation of ER␣ or ER␤ mRNA expression in human uterine artery endothelial cell (HUAEC) nuclear extracts on stimulation with 17␤-estradiol for 1 or 2 h. By contrast, Western analysis on HUAEC extracts revealed that 17␤-estradiol was capable of down-regulating both ER␣ and ER␤ protein starting 1 h after treatment, an effect that can be blocked by pretreatment with tamoxifen as well as with the proteasome inhibitor lactacystin. The proteolysis inhibitors insulin, cycloheximide, and puromycin impede ER␣, but not ER␤, turnover. Ubiquitin, but not its competitive inhibitor methyl-ubiquitin, induces rapid turnover of both ERs in a cell-free system of MCF-7 and HUAEC extracts. We, thus, propose the existence of estrogen-induced ER degradation that serves to control physiological responses in an estrogen target tissue, i.e. T HE INCIDENCE OF cardiovascular disease is lower in premenopausal women than in men, but it increases after menopause (1). It has, thus, been proposed that estrogen has a cardioprotective effect (2). However, the Heart and Estrogen/Progestin Replacement Study (HERS), a randomized, placebo-controlled secondary prevention trial of conjugated estrogen with progestin, found no overall reduction in coronary events among women assigned to active hormone treatment (3), thereby raising new questions about the mechanism of estrogen action within the vessel wall.
T HE INCIDENCE OF cardiovascular disease is lower in
premenopausal women than in men, but it increases after menopause (1) . It has, thus, been proposed that estrogen has a cardioprotective effect (2) . However, the Heart and Estrogen/Progestin Replacement Study (HERS), a randomized, placebo-controlled secondary prevention trial of conjugated estrogen with progestin, found no overall reduction in coronary events among women assigned to active hormone treatment (3), thereby raising new questions about the mechanism of estrogen action within the vessel wall.
Estrogens influence gene expression, growth, and cellular differentiation in target cells by activating one or both of two estrogen receptors (ER), ER␣ and ER␤ (4, 5) . ERs have been studied intensely in female reproductive physiology, but functional ERs are also present and physiologically important in other tissues of both sexes, including the brain, bone, liver, skin, and the cardiovascular system (6) .
Regulation of ER concentration is a key component in limiting estrogen responsiveness in target cells. The level of ER␣ in cells changes with varying physiological states. In most cases, the primary endocrine regulator is the ligand itself. In an autoregulatory feedback loop, estrogen induces a decline in both ER␣ protein and mRNA (7) . Recently, a nongenomic action of estrogen that involves nuclear ER␣ has been described, whereby rapid proteolysis of ER␣ protein occurs via a proteasome-mediated pathway (8, 9) . The ubiquitin-proteasome system is responsible for the degradation of many of the short-lived proteins in eukaryotic cells. The pathway targets proteins for degradation by the proteasome via covalent tagging of the substrate protein with a polyubiquitin chain. The multi-ubiquitinated substrate protein is then degraded by the 26 S proteasome in an ATP-dependent reaction (10) . In contrast to ER␣, however, there are no data available on whether or not ER␤ could also be a target of ligand-mediated turnover.
ER␣ and ER␤ are both expressed in vascular endothelial and smooth muscle cells (11) . Vascular ER␤ mRNA expression was found to be increased after balloon injury in mice aorta (12) , and abnormal vascular function as well as hypertension was shown in mice deficient in ER␤ (13) . Yet the mechanisms governing ER␣ and ER␤ concentration in vascular endothelial cells are undetermined.
In the present study, we used cultured human uterine artery endothelial cells (HUAEC) as well as a MCF-7 breast cancer cell line to explore regulation of one or both of the two ERs, ER␣ and ER␤, by estrogen.
Materials and Methods

Endothelial cell culture
Vessel segments of the uterine artery were excised within 3 h after hysterectomy and immersed in ice-cold (4 C) Hanks' balanced salt solution (Sigma, St. Louis, MO) containing antibiotics (penicillin, streptomycin, and fungizone, BioWhittaker, Inc., Verviers, Belgium) and 5% fetal calf serum (FCS, Pan Biotech, Aidenbach, Germany). Surrounding tissue was removed, and vessel segments were cut open and incubated in 0.2% collagenase type IV (Pan Biotech) at 37 C for 10 -20 min to detach endothelial cells from the surface. Cell suspension was filtered through a cell strainer with 100-m pores (Becton Dickinson and Co., Franklin Lakes, NJ). Cells were washed with Hanks' balanced salt solution containing 5% FCS (wash solution) at 4 C, centrifuged for 5 min at 1500 ϫ g at 4 C, and resuspended in wash solution. The cell suspension was then mixed with M 450 rat-antimouse-mouse-antihuman CD 31 dynabeads Abbreviations: CHX, Cycloheximide; E 2 , 17␤-estradiol; ER, estrogen receptor; FCS, fetal calf serum; HUAEC, human uterine artery endothelial cell; MeUb, methylated ubiquitin; PUR, puromycin; TAM, tamoxifen.
for 10 min and washed five times with cold wash solution to remove unbound cells. Cells with beads were resuspended in M199 medium containing 20% FCS with antibiotics, heparin (5 U/ml; Immuno, Vienna, Austria), endothelial cell growth supplement (40 g/ml; Technoclone Inc., Vienna, Austria), and l-glutamine (2 mmol/liter; BioWhittaker, Inc.). Cells, denominated HUAEC (14) , were grown and passaged at 37 C under 5% CO 2 /95% air. HUAEC were subcultured using a split ratio of 1:2. The endothelial origin was confirmed by typical cobblestone morphology, immunofluorescence staining with antibodies against von Willebrand factor, angiotensin converting enzyme, and Ulex Europaeus I lectin, as well as uptake of acetylated low-density lipoprotein. The medium was replaced every 2 d.
Confluent passage four cells were maintained in phenol red-free medium containing 10% charcoal-filtered FCS for at least 48 h before induction with hormones. Cells were then treated with 17␤-estradiol (E 2 ) for various times and concentrations. Additionally, 30 min before E 2 , cells were treated with the partial ER antagonist tamoxifen (TAM, 10 Ϫ6 m), insulin (10 Ϫ6 m), the proteasome inhibitor lactacystin (25 m), and the protein synthesis as well as proteolysis inhibitors cycloheximide (CHX, 50 m) and puromycin (PUR, 50 m), or respective vehicles for agonists.
Western analysis
Nuclear and cytoplasmic fractions were prepared from cells using a commercially available nuclear and cytoplasmic extraction reagent kit (NE-PER, Pierce Chemical Co., Rockford, IL) according to the manufacturer's instructions. Protein concentrations were measured by spectrophotometry using the MicroBCA-Protein Assay Reagent from Pierce Chemical Co.
A total of 25 g of nuclear extracts were used for experiments, and 1 g of a recombinant human (rh) ER␣ protein (Affinity BioReagents, Inc., Golden, CO) or a rhER␤ protein (Alexis Biochemicals, San Diego, CA) was used as positive control for detection of ER␣ and ER␤ protein, respectively. After quantification, proteins were electrophoresed by the use of SDS-PAGE on ExcelGel 8 -18% gradient gels (Amersham Pharmacia Biotech, Uppsala, Sweden) and transferred onto nitrocellulose membranes (Amersham Pharmacia Biotech). Membranes were blocked in PBS containing 2.5% nonfat dry milk, 2.5% BSA (Sigma), and 0.05% Tween 20 (Promega Corp., Madison, WI) for at least 1 h. Immunoreactions were performed with either an anti-ER␣ (AB-10, Neomarkers, Fremont, CA) or an anti-ER␤ (6B12, Genetex, San Antonio, TX) monoclonal antibody (1 g/ml each). A monoclonal mouse IgG1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used at 1 g/ml instead of the primary antibodies as negative control for each antibody. Antibody to IB␣ (C21, Santa Cruz Biotechnology, Inc.) was used to visualize protein not regulated by estrogen in endothelial cells and as a loading control (15) . The antibody hybridization was followed by a horseradish peroxidase-conjugated goat antimouse-IgG (40 ng/ml; Pierce Chemical Co.). Specific reaction products were detected by the SuperSignal West Pico Chemoluminescent Substrate kit (Pierce Chemical Co.) according to the manufacturer's instructions.
Assay of in vitro ER breakdown in MCF-7 and HUAEC nuclear extracts
To investigate whether turnover of ER␣ and/or ER␤ in nuclear extracts from untreated HUAEC or MCF-7 cells (positive control) was through the ATP-ubiquitin proteolytic pathway, we performed in vitro ER␣ and ER␤ protein degradation assays using a previously described method (16) that was slightly modified as follows: the reaction mixture contained, in a final volume of 50 l, 10 g nuclear extract of MCF-7 cells and 30 g nuclear extract of HUAEC, 50 mm Tris-HCl (pH 7.6), 5 mm MgCl 2 , 3 mm dithiothreitol, 4 mm ATP, 10 mm creatine phosphate, 5 g creatine phosphokinase (ATP-generating system), and either 4 g ubiquitin (Sigma) or 40 g methyl-ubiquitin (Sigma) for 2 h at 37 C. Reactions were separated by boiling samples in the presence of SDSloading buffer [100 mm Tris-HCl (pH 8.0)/200 mm dithiothreitol/4% SDS/20% glycerol/0.2% bromophenol blue]. The reaction mixtures were resolved by 8 -18% SDS-PAGE, and reaction products were visualized by Western analysis using the ER antibodies described above.
RT-PCR
RNA extraction and reverse transcription. Pure total RNA was extracted from cultured endothelial cells by isopyknic centrifugation and treated with DNAse I (Roche Molecular Biochemicals, Indianapolis, IN) as described (17) . cDNA was synthesized in 50 l total volume containing the commercially available Random Primed Reverse Transcription Reaction Mix (ViennaLab, Vienna, Austria), 40 U RNasin (Promega Corp.), 400 U -MLV Reverse Transcriptase (ViennaLab), and 1 g total RNA. Reactions were incubated at room temperature for 10 min, followed by 50 min at 37 C and 5 min at 95 C.
DNA amplification. PCRs were performed on a Perkin-Elmer GeneAmp PCR System 2400 (Perkin-Elmer Corp., Norwalk, CT). PCR was performed in a total volume of 25 l containing 3 l cDNA template, 25 pmol of each primer (all primer sequences and mapping positions are listed in Table 1 ; primers for ER␣ are located in exons 4 and 6; primers for ER␤ are located in exon 4), 250 m deoxynucleoside triphosphates, 10 mm Tris-HCl (pH 9.0), 50 mm KCl, 0.01% (wt/vol) gelatin, 1.5 mm MgCl 2 , 0.1% Triton X-100, and 0.5 U Super Taq DNA Polymerase (ViennaLab). To control for errors in input of cDNA used in PCRs, amplification of the ubiquitous ␤-2-microglobulin cDNA was performed in parallel using ␤-2-microglobulin-specific primers. The amplification profiles were as follows: 94 C for 30 sec, 50 C (␤-2-microglobulin and ER␤) or 48 C (ER␣) and 72 C for 30 sec; 35 (ER␣ and ER␤) or 22 (␤-2-microglobulin) cycles. To ensure that these PCR systems work in a quantitative way, all of them were thoroughly optimized with respect to their exponential amplification phase. This was done by using different reaction times, reaction temperatures, and cycle numbers as well as different concentrations of reaction components. To simplify the performance and to increase the reproducibility of PCR, PCR master mixes containing primers, deoxynucleoside triphosphates, and buffer were prepared and used in all amplification reactions. In addition, tubes containing all PCR components and distilled water instead of cDNA served as negative controls to check for the presence of DNA that may have been carried over from prior reactions. All PCRs were performed at least twice in separate experiments.
PCR product analysis. PCR products (ER␣, 213 bp; ER␤, 130 bp; ␤-2-microglobulin, 231bp) were separated on agarose gels [5-10 l PCR product; 3% SB Fine Gel Agarose (Severn Biotech Ltd., Kidderminster, UK)] and visualized by performing the electrophoresis on SYBR Green I (Molecular Probes, Inc., Eugene, OR) -containing gels.
Quantitative real-time RT-PCR. cDNA was synthesized from total RNA as described above. The amplification primers and the TaqMan probe (Table 2) for the ER␤ real-time PCR were designed with the PrimerExpress software (PE Applied Biosystems, Foster City, CA). The ER␤ forward primer binds in exon 1, and the ER␤ reverse primer binds in exon 2. FAM (6-carboxyfluorescein) was used as the reporter dye, and TAMRA (6-carboxy-tetramethylrhodamine) was used as the quencher dye. Oligonucleotide synthesis and purification were done by VBCGenomics Bioscience Research GmbH (Vienna, Austria). The reaction was performed in 25 l total volume containing 4 l cDNA, 25 pmol of each amplification primer, 5 pmol probe, and 12.5 l 2ϫ TaqMan Universal Mix (PE Applied Biosystems). The reaction conditions were 50 C for 2 min, 95 C for 10 min (activation of the AmpliTaq-Gold Polymerase), and then 40 cycles of 15 sec at 95 C (denaturation) followed by 60 sec at 60 C (annealing and extension). To correct variations linked to differences in the amount of RNA taken for the reaction or to different levels of inhibition during RT or PCR, we normalized the ER␤ expression using the ␤-2-microglobulin gene, a ubiquitously expressed housekeeping gene, as a reference gene. The expression of this housekeeping gene was quantified with the ␤-2-microglobulin Control Reagents Kit from PE Applied Biosystems, according to the manufacturer's guidelines. All ER␤ and ␤-2-microglobulin experiments were performed in triplicate, and several negative controls were included. Fluorescence emission was continuously monitored and analyzed by a GeneAmp 5700 Sequence Detection System (PE Applied Biosystems) with the GeneAmp 5700 SDS Software (version 1.1).
Standard curves
For the generation of ER␤ and ␤-2-microglobulin standard curves, we used 2-fold serial dilutions of the HUAEC cDNA sample, which showed the highest ER␤ mRNA expression levels in ER␤ real-time RT-PCR, as templates. Standard curves were constructed and calculated by the GeneAmp 5700 SDS software referring the threshold cycle (PCR cycle at which a specific fluorescence becomes detectable) to the log of the cDNA starting quantity of each dilution step. These standard curves allowed us to interpolate the unknown ER␤ and ␤-2-microglobulin mRNA expression levels in each analyzed sample.
Results
Specificity of antibodies
A rhER␣ and a rhER␤ protein as well as extracts from separated nuclear fractions of HUAEC were subjected to standard SDS electrophoresis, transferred to a membrane, and probed with ER␣ and ER␤ antibodies. The results shown in Fig. 1 demonstrate the presence of an immunoreactive protein fraction with an apparent molecular mass of approximately 67 kDa recognized by the ER␣ antibody with the rhER␣ protein (Fig. 1A) , the HUAEC or the MCF-7 extract, but not the rhER␤ protein (Fig. 1A) , whereas an immunoreactive protein with a molecular mass of approximately 55 kDa was recognized by the ER␤ antibody with the rhER␤ protein as well as with the HUAEC and MCF-7 extract, but not with the rhER␣ protein (Fig. 1B) . However, a somewhat larger protein band was detectable within both HUAEC and MCF-7 extracts compared with rhER␤ protein. These apparent differences may reflect protein species microheterogeneity in posttranslational modifications, such as phosphorylation (18) . Parallel experiments with isotype monoclonal antibodies failed to produce a distinctive band in these regions and confirmed the specificity of the 67-or 55-kDa proteins toward both ER antibodies used (data not shown).
Effects of estrogen or combined estrogen/TAM treatment on ER protein levels in HUAEC
The cytosolic fractions from HUAEC equally lacked or exhibited only a faint immunostained band (data not shown). E 2 at a concentration such as that attained during the ovulatory phase of the menstrual cycle (10 Ϫ10 m) down-regulated both ER␣ and ER␤ protein after 1 h (Figs. 2-5 ) and 2 h (data not shown) of E 2 administration, whereas a 30-min pretreatment with TAM blocked both ER␣ and ER␤ degradation (Figs. 2-5 ). The amount of down-regulation was comparable at either concentration of E 2 used in these experiments (Figs.  2 and 3) . Ϫ6 M for 30 min before E 2 . A, Representative Western blot analysis of protein in nuclear cell extract. B, Quantification of dose response analysis of ER␣ response was performed by laser densitometry. Cumulative data from three independent experiments are shown. Relative ER␣ levels are represented by the mean Ϯ SD relative to E 2 -treated cells. Statistical analysis by ANOVA followed by Student's paired t test indicates that E 2 treatment results in a significant decrease in ER␣ levels (*, P Ͻ 0.001), whereas TAM pretreatment completely blocked ER␣ decrease.
TABLE 2. Amplification primers and TaqMan probe
Name Sequence ER␤-forward primer 5Ј-GATCGCTAGAACACACCTTACCTGTA-3Ј ER␤-reverse primer 5Ј-GAAGTGAGCATCCCTCTTTGAAC-3Ј ER␤-TaqMan probe 5Ј-AACCGTTGCGCCAGCCCTGTT-3Ј
Effects of lactacystin, insulin, CHX, and PUR treatment on E 2 -induced ER elimination
Rapid proteolysis of ER␣, at least in MCF-7 cells (9) and lactotrope cells of the anterior pituitary (8) has recently been shown to occur mainly via a proteasome-mediated pathway. We therefore assessed the potential implication of the proteasome complex in E 2 -mediated ER␣ and ER␤ elimination in HUAEC. Remarkably, lactacystin (a highly specific, irreversible proteasome inhibitor; Ref. 19 ) abrogated both ER␣ and ER␤ elimination (Figs. 4 and 5) . By contrast, insulin, a naturally occurring inhibitor of cellular proteolysis, acting at least in part by decreasing the ubiquitin-mediated proteasomal activity of its target cells (20) , abrogated E 2 -induced ER␣, but not ER␤, elimination in HUAEC (Figs. 4 and 5) , suggesting that ER␣ but not ER␤ turnover is a target of insulin action in human vascular endothelial cells.
Addition of 50 m CHX to the medium 30 min before E 2 treatment abrogated the effect of E 2 on ER␣ but not ␤ (Figs.  4 and 5) , establishing the involvement of protein synthesis in vascular endothelial cell ER␣, but not ER␤, turnover. Of note, when CHX was replaced by PUR, which also blocks ER␣ down-regulation (21), a similar decrease of ER␣ turnover was observed (data not shown), refuting the possibility of potential artifact associated with the use of only one protein synthesis/proteolysis inhibitor. To further verify that the decrease in protein was specific for ER, blots were reprobed with antibody against the ubiquitous protein, IB␣, which is not regulated by estrogen. IB␣ protein levels were unchanged in the presence and absence of E 2 and, thus, served as both a loading control for total protein content and a standardization of ER levels (Fig. 4) .
From that data, a major difference in the metabolic degradative pathways following binding of E 2 to ER␣ or ER␤ should be considered.
ATP-dependent degradation of ER in MCF-7 and HUAEC nuclear extracts
In an effort to examine the role of the ubiquitin-proteasome pathway in ER␣ and/or ER␤ degradation, we used a cell-free system modified from Hershko et al. (16) . With that system, we aimed at discovering whether or not endogenous MCF-7 ER␣ degradation, which has been reported to occur via proteasome-mediated proteolysis (8, 9) , MCF-7 ER␤ degradation, and HUAEC ER␣ and/or ER␤ degradation are ubiquitin dependent. For that purpose, we examined the specificity of the ATP-dependent degradation in nuclear extracts by using wild-type ubiquitin, or an inhibitor directed HUAEC were treated and analyzed as described in Fig. 2 , apart from the fact that an antibody to human ER␤ was used. Statistical analysis revealed that E 2 treatment results in a significant decrease in ER␤ levels (*, P Ͻ 0.001), whereas TAM pretreatment completely blocked that decrease. Ϫ10 M (E 2 ), and nuclear extracts were generated. Upper panel, A representative Western analysis of ER␣ protein in HUAEC nuclear extracts. Lower panel, Anti-IB␣ Western analysis of these extracts as a loading control. B, Quantification of ER␣ response was performed by laser densitometry using IB␣ levels to standardize ER␣ levels. Relative ER␣ levels in E 2 -treated cells are represented by the mean Ϯ SD relative to untreated (0) or pretreated cells. Statistical analysis by ANOVA followed by Student's paired t test indicates that E 2 treatment results in a significant decrease in ER␣ levels (***, P Ͻ 0.001), whereas pretreatment with TAM, lactacystin, insulin, or CHX completely blocked ER␣ decrease.
at the ubiquitin-substrate conjugation reactions, methylated ubiquitin (MeUb). Proteins are tagged for recognition by the 26 S proteasome via the conjugation of a polyubiquitin chain to the targeted protein (10) . This polyubiquitin chain is generated by isopeptide linkages between the carboxy terminus of each ubiquitin molecule with lysine 48 of the preceding ubiquitin. This process is competitively inhibited by MeUb (22) . Thus, MeUb was added in an amount recently shown to be sufficient for inhibition of MyoD degradation in HeLa nucleoplasm (23) to overcome the effect of endogenous ubiquitin. As seen in Fig. 6 , the ATP-dependent degradation of both ER␣ and ER␤ is inhibited by MeUb in both MCF-7 cells and HUAEC to a different extent. This difference might be most attributable to the lesser amount of intrinsic nuclear degradation machinery within endothelial nuclear extracts compared with MCF-7 nuclear extracts, however this remains to be clarified. This inhibition is not seen by the addition of wild-type ubiquitin in either case. These data indicate that the ubiquitin-proteasome pathway is responsible for the ATP-dependent degradation of both ER␣ and ER␤ in MCF-7 breast cancer cells, as well as in HUAEC.
Effects of estrogen or combined estrogen/TAM treatment on ER mRNA levels in HUAEC
To examine a potential involvement of E 2 -mediated ER turnover at the level of transcription, total RNA was extracted from cells treated with indicated E 2 concentrations for 1 h (Fig. 7 ) or 2 h (data not shown) or with TAM 30 min before 10 Ϫ10 m E 2 , and cell extracts were then analyzed by means of RT-PCR for ER␣ mRNA (Fig. 7) and ER␤ mRNA (data not shown) as well as quantitative real-time RT-PCR for ER␤ mRNA expression (data not shown). We did not find any difference in the amount of ER␣ and ER␤ mRNA expression levels after E 2 administration in HUAEC.
Discussion
The relationship between estrogens and vascular disease is poorly understood. However, evidence exists that estrogens have rapid effects on the vascular wall, which are probably mediated through ERs (24) .
The aim of this study was to determine the influence of the natural estrogen, E 2 , on the concentration of ER␣ and ER␤ in human vascular endothelial cells. Our main result is that even low concentrations of E 2 induce a substantial downregulation of vascular endothelial ER␣ as well as ER␤ protein starting after 1 h of incubation with E 2 . This down-regulation on the protein level is not accompanied by a similar decrease in the amount of respective mRNA, indicating that transcription is not involved in that process. These data suggest that ER␣ is implicated in targeted down-regulation in vascular endothelial cells that is comparable to targeted ER␣ down-regulation in HeLa cells (25) , MCF-7 breast cancer cells (9) , as well as lactotrope cells of the anterior pituitary (8) , by the natural ligand estrogen. Moreover, our data introduce ER␤ as a target of ligand-mediated down-regulation, at least in endothelial cells. We next aimed to explore whether the partial estrogen receptor antagonist TAM is able to affect ER␣ and ER␤ turnover in endothelial cells. We found TAM acting as an antagonist of E 2 -mediated ER␣ and ER␤ degradation in our cells. In addition to its effect to relax precontracted rabbit coronary arteries (26) , our finding that TAM increases ER␣ and ER␤ bioavailibility in vascular endothelium may also contribute to the evidence that TAM is associated with a reduction in the incidence of fatal myocardial infarction in women (27) .
According to previous data exhibiting the proteasome pathway as the major system for selective ATP-dependent nongenomic degradation of ER␣ by the natural ligand estrogen (8, 9, 25) , we asked whether inhibitors of the proteasome pathway were able to reduce the in vitro degradation of ER␣ and/or ER␤ in vascular endothelium. First, we found lactacystin, an irreversible proteasome inhibitor as markedly effective to inhibit ER␣ as well as ER␤ degradation, demonstrating that both vascular endothelial ER␣ and ER␤ protein are turned over through the proteasome pathway. Second, we found insulin, a naturally occurring, reversible inhibitor of protein degradation (28) , as effective to inhibit ER␣, but not ER␤, turnover in endothelial cells. Insulin promotes cellular growth and maintenance by a wide variety of anabolic and anticatabolic actions, including the inhibition of overall proteolysis (28) . However, the proteolytic systems regulated by insulin are unclear. We now demonstrate that ER␣ but not ER␤, turnover is a target of insulin inhibition in our endothelial cells. Although not shown here, this selective effect of insulin might most likely be due to activation of a FIG. 5. Effect of proteasome inhibitors on ER␤ degradation. HUAEC were treated and analyzed as described in Fig. 4 , apart from the fact that an antibody to human ER␤ was used. Statistical analysis revealed that E 2 treatment results in a significant decrease in ER␤ levels (***, P Ͻ 0.001), whereas pretreatment with TAM and lactacystin, but not with insulin or CHX, completely blocked ER␤ decrease.
signaling pathway that inhibits ubiquitin ligase activity, which is specific for ER␣, but not ER␤. However, experiments are needed to reject or validate this point of view.
In addition to being insensitive to insulin, we found that ER␤ turnover is not compromised after treatment with CHX and PUR that have recently been implicated to compromise ER␣ turnover in MCF-7 cells through proteolysis inhibition, but not protein synthesis inhibition (21) . This led us to hypothesize the presence of at least two proteasomal uptake mechanisms existing in our endothelial cells, which differ according to the ER implicated: a mechanism blocked by inhibition of proteolysis, which emerges in the presence of CHX, PUR, and insulin, specific for ER␣ bioavailibility; and a mechanism unaffected by proteolysis inhibition, specific for ER␤ turnover. Previous work suggested that CHX may block the synthesis of an enzyme involved in the cascade of events leading to ubiquitination of ER␣ (9) . We therefore attempted to explore whether ubiquitin contributes to ER␣ and/or ER␤ turnover in vascular endothelium. For that purpose, we used a cell-free system consisting of nuclear extracts from either MCF-7 cells, used as a control system for turnover of ER␣, or uterine artery endothelial cells. Interestingly, we found the degradation of ER␣ as well as that of ER␤ in MCF-7 cells and HUAEC dependent on ubiquitin. The findings on ER␣ turnover correspond with previous data obtained from within MCF-7 cells (8, 9) . In addition to ER␣, we now intro- duce ER␤ as a target of the ubiquitin-proteasome system, at least in MCF-7 breast cancer cells and HUAEC. However, the mechanisms by which inhibition of proteolysis selectively operates on ER␣, but not ER␤, deserves further clarification.
Based on our findings, according to the nature of ER involved, we propose the existence of two different ubiquitindependent proteasomal uptake mechanisms that compromise estrogen receptor turnover in human vascular endothelial cells. It is likely that both systems contribute to selective modulation of ER dynamics in uterine artery vascular endothelium, dependent on the orchestrated nature of a wide variety of vasoactive agonists. FIG. 7 . Concentration course of ER␣ and ER␤ mRNA expression in response to E 2 in HUAEC. Cells were treated with E 2 with indicated concentrations. Total RNA was extracted, and RT-PCR was performed using primers specific for ER␣, ER␤, and ␤-2-microglobulin. ER␣ mRNA levels were normalized to ␤-2-microglobulin mRNA levels in the same lane to correct for loading differences. Data are presented relative to the EtOH control, which is arbitrarily set as 100%. ER␣ mRNA levels in HUAEC do not change in response to E 2 treatment for 1 h.
